CYP2U1 and breast carcinoma: Therefore, in view of the obvious discrepancy in the expression of CYP2U1 in diverse molecular types of tumor specimens, the level of CYP2U1 may have a certain reference value in the selection of therapeutic regimen for breast cancer patients, and predicts that the patients with high CYP2U1 expression, have adverse clinical outcomes.